Omapatrilat
CAS No. 167305-00-2
Omapatrilat( BMS-186716 )
Catalog No. M12553 CAS No. 167305-00-2
A potent, dual inhibitor of the metalloproteases ACE and NEP with Ki of 0.64 nM and 0.45 nM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 74 | Get Quote |
|
| 50MG | 512 | Get Quote |
|
| 100MG | 896 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameOmapatrilat
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, dual inhibitor of the metalloproteases ACE and NEP with Ki of 0.64 nM and 0.45 nM, respectively.
-
DescriptionA potent, dual inhibitor of the metalloproteases ACE and NEP with Ki of 0.64 nM and 0.45 nM, respectively; shows moderate activity against APP, and low activity against ECE1; causes significant inhibition of plasma ACE and increases plasma renin activity, reduces blood pressure in spontaneously hypertensive rats; orally active.Hypertension Discontinued.
-
In VitroOmapatrilat exhibits high potency for NEP, NEP2 and ACE, moderate strong activity against APP, but low activity against ECE1 (Ki=0.45, 25, 0.64, 250 nM) . In vitro autoradiography using the specific NEP inhibitor radioligand 125I-RB104 and the specific ACE inhibitor radioligand 125I-MK351A show omapatril at (10 mg/kg) causes rapid and potent inhibition of renal NEP and ACE, respectively, for 24 h.
-
In VivoOmapatrilat demonstrates excellent blood pressure lowering in a variety of animal models characterized by various levels of plasma renin activity and significantly potentiates urinary sodium, ANP, and cGMP excretion in a cynomolgus monkey assay. Omapatrilat decreases mean arterial pressure (MAP) approximately 40 mmHg below baseline from 10 to 24 h. Oral administration of omapatrilat at 100 μM/kg once daily results in a 38 mmHg decrease in systolic blood pressure at day three as compared to vehicle . Omapatrilat is widely used in experimental protocols related to hypertension and heart failure. Chronic oral administration of omapatrilat reduces aortic leakiness and atheroma formation with enhanced endothelial independent vasorelaxation to ANP. Omapatrilat causes significant inhibition of plasma ACE and increased plasma renin activity in rats.
-
SynonymsBMS-186716
-
PathwayMetabolic Enzyme/Protease
-
TargetACE
-
RecptorACE
-
Research AreaCardiovascular Disease
-
IndicationHypertension
Chemical Information
-
CAS Number167305-00-2
-
Formula Weight408.5349
-
Molecular FormulaC19H24N2O4S2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 31 mg/mL
-
SMILESO=C([C@@H]1CCC[C@](N21)([H])SCC[C@H](NC([C@@H](S)CC3=CC=CC=C3)=O)C2=O)O
-
Chemical Name7H-Pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid, octahydro-4-[[(2S)-2-mercapto-1-oxo-3-phenylpropyl]amino]-5-oxo-, (4S,7S,10aS)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Robl JA, et al. J Med Chem. 1997 May 23;40(11):1570-7.
2. Fryer RM, et al. Br J Pharmacol. 2008 Mar;153(5):947-55.
3. Burrell LM, et al. Am J Hypertens. 2000 Oct;13(10):1110-6.
molnova catalog
related products
-
Lisinopril dihydrate
A angiotensin-converting enzyme (ACE) inhibitor for treatment of hypertension, heart failure, and after heart attacks.
-
Zabicipril HCl
Zabicipril HCl(S 9650) is a potent angiotensin-converting enzyme inhibitor.
-
Temocaprilat
Temocaprilat is an Angiotensin-converting Enzyme (ACE) inhibitor.
Cart
sales@molnova.com